Other Events ·
Enanta advances zelicapavir program with registrational Phase 2b/3 RSV trial in high-risk adults and pediatric study
ENTAEnanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc. announced the advancement of its zelicapavir clinical development program for the treatment of respiratory syncytial virus (RSV), including plans for a registrational Phase 2b/3 clinical trial in high-risk adults and a Phase 2b clinical trial in pediatric patients. Enanta Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing small molecule drugs for infectious diseases.